Basic Information
Nanogenics is a leading RNA therapeutics company dedicated to addressing significant unmet needs in ophthalmology and oncology. Our lead product, ECP-105, is our novel glaucoma treatment. We anticipate it will enter clinical trials in 2025, followed by several other promising drugs.
Nanogenics Limited
United Kingdom
less than 15 people
January 01, 2011
--